Zealand stock fell as much as 32% after after the company reported weaker-than-expected data from a midstage study of a drug candidate it is developing with Roche.
March 6 (Reuters) - Shares in Zealand Pharma tumbled more than 30% on Friday, putting the Danish biotech firm on track for its worst trading day on record, after mid-stage trial results for obesity ...
Find latest healthcare news from every corner of the globe at Reuters.com, your online source for breaking international news ...
Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum /Besu and Corda (R3) selected as most suitable blockchain ...
Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...
Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...
1don MSN
This Danish biotech’s new weight-loss drug disappointed investors, and its stock is tumbling
Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.
Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. The erosion was obvious. After MSN Pharmaceuticals opened the floodgates to Entresto generics in ...
A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...
From miracle weight-loss fix to mass tort battleground: drugs like Ozempic and Mounjaro promise better health — but also ...
Corden Pharma Colorado Inc., a developer and manufacturer of peptide drug substances, has leased the 64,000-square-foot 5505 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results